Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Walgreens Boots Alliance ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and ...

Shares of Axsome Therapeutics ( AXSM -0.40%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Operator Good morning, and welcome to the Axsome Therapeutics fourth quarter and full year 2024 conference call. Currently, all participants are in listen-only mode. Later, there will be a ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.